Discussion In this phase 2, randomized, double-blind, placebo-controlled trial of orforglipron, participants in all dose cohorts (12, 24, 36, and 45 mg) had a greater decrease from baseline in body weight than those in the placebo group, both at 26 weeks (primary end point) and at 36 weeks (secondary end point)
The GLP-1 mechanism works differently in this population, and the glucagon-suppressing effect of the drug can cause dangerous hypoglycemia
Your care is led by Chloe, RN, a Registered Nurse and Clinical Aesthetic Nurse Injector at InjectCo
Similar to Ozempic in their mode of action, these drugs may have slightly different dosing or administration guidelines